Kyntra Bio returns to profit in Q3 as revenue rises
Overview
Rare disease biopharmaceutical's Q3 revenue from continuing operations rose yr/yr
Net income from continuing operations for Q3 was $0.2 mln, reversing a loss last yr
Company completed royalty financing agreement restructuring, reducing payment obligations by $60 mln
Outlook
Company plans to start Phase 3 roxadustat trial in 1Q 2027, pending partnership or capital raise
Kyntra Bio expects to reduce operating expenses by over $20 mln in 2027 and 2028
Company expects cash and equivalents to fund operations into 2028
Result Drivers
PROGRAM TERMINATIONS - Co discontinued development of FG-3246 and FG-3180 after interim analysis showed insufficient efficacy, resulting in expected operating expense reductions over $20 mln in 2027 and 2028
ROYALTY AGREEMENT RESTRUCTURING - Co restructured royalty financing agreement, reducing maximum aggregate payment obligation by $60 mln, leaving only $15 mln in future royalty-backed payments
PIPELINE FOCUS - Co said it is focusing on rare disease portfolio, planning a pivotal Phase 3 trial for roxadustat in LR-MDS patients, subject to partnership or capital raise
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | $157,000 | ||
Q3 Net Income from Cont Ops | $157,000 | ||
Q3 Revenue from Cont Ops | $1.76 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Kyntra Bio, Inc. is $38.00, about 1,004.7% above its November 13 closing price of $3.44
Reuters Recommended Reads
Nov 13 - Canada's IM Cannabis Q3 revenue falls sharply, net loss widens
Nov 16 - Rhythm drug shows sustained weight reduction in patients with brain damage-related obesity
Nov 16 - Canada's Helus Pharma Q2 net loss widens on higher operating expenses
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)